Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 378-384

  Carotenuto, Pietro ^a   Roma, Cristin ^a   Cozzolino, Salvatore ^b   Fenizia, Francesca ^a   Rachiglio, Anna Maria ^a   Tatangelo, Fabiana ^a   Iannaccone, Alessia ^a   Baron, Luigi ^c   Botti, Gerardo ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Ospedale S Leonardo   (Italy)

Author keywords

Anti EGFR therapy; Co amplification at lower denaturation temperature PCR; Colorectal carcinoma; Epidermal growth factor receptor; KRAS; Mutations

Indexed keywords

K RAS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CO AMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; COLORECTAL CANCER; CONTROLLED STUDY; DILUTION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TUMOR GENE; WILD TYPE;

BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE;

EID: 84855691413     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1221     Document Type: Article

References (21)

1. Malumbres M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465, 2003. (Pubitemid 37328850)
2. Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308, 2007. (Pubitemid 46480970)
3. Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006. (Pubitemid 43199589)
4. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
5. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E and Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527, 2009.
6. van Krieken JH, Jung A, Kirchner T, et al: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 454: 233-235, 2009.
7. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
8. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
9. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009.
10. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
11. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.
12. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA and Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27: 1130-1136, 2009.
13. Carotenuto P, Roma C, Rachiglio AM and Normanno N: Letter to the editor: reply to Kobunai et al. Pharmacogenomics 12: 309-310, 2011.
14. Carotenuto P, Roma C, Rachiglio AM, et al: Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11: 1169-1179, 2010.
15. Li J, Wang L, Mamon H, Kulke MH, Berbeco R and Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14: 579-584, 2008. (Pubitemid 351655208)
16. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
17. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705, 2010.
18. Zuo Z, Chen SS, Chandra PK, et al: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22: 1023-1031, 2009.
19. Pritchard C, Akagi L, Reddy P, Joseph L and Tait J: COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. BMC Clin Pathol 10: 6, 2010.
20. Song C, Milbury CA, Li J, Liu P, Zhao M and Makrigiorgos GM: Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis. Diagn Mol Pathol 20: 81-89, 2011.
21. Tol J, Dijkstra JR, Vink-Borger ME, et al: High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 14: 2122-2131, 2010.